Clover Health's Chief Legal Officer Karen Soares Sells Shares

Karen Soares, the Chief Legal Officer of Clover Health Investments, sold 4,681 shares of the company's stock on June 15, 2026. This planned transaction was executed at an average price of $4.61 per share, amounting to a total value of approximately $21,579.

Insider Buying and Selling at Clover Health Investments, Corp.

On June 15, 2026, Karen Soares executed a planned sale of 4,681 shares at $4.61 each. Other recent insider activity includes Jamie Reynoso, CEO of Medicare Advantage, selling 6,350 shares at the same price on the same day. Earlier, Reynoso also sold 7,289 shares on June 11 at $4.91. These transactions were part of planned sales, reflecting strategic decisions by the company's executives.

Other Institutional Activity in Clover Health

Several institutional investors have recently adjusted their positions in Clover Health. BlackRock, Inc. trimmed its stake by 440,347 shares, holding 31,840,512 shares valued at about $56 million. In contrast, Vanguard Capital Management LLC added 16,982,073 shares, now holding the same number of shares worth approximately $29.9 million. Geode Capital Management, LLC increased its position by 264,302 shares, totaling 10,055,510 shares valued at around $17.7 million. State Street Corp also raised its holdings by 239,706 shares, ending with 9,559,889 shares worth about $16.8 million.

Clover Health Stock Snapshot

Clover Health's shares, trading under the ticker CLOV on the NasdaqGS, were recently priced at $4.905. The company has a market capitalization of approximately $2.53 billion and a forward P/E ratio of 48.1, indicating expectations of future earnings growth. With a beta of 2.484, the stock is considered quite volatile. The stock's 52-week range spans from $1.58 to $5.18, with moving averages of $3.1154 over 50 days and $2.673775 over 200 days. Clover Health maintains a current ratio of 1.331 and a quick ratio of 1.207, reflecting its ability to cover short-term liabilities.

Recent Earnings

Clover Health reported revenue of about $2.21 billion, achieving a revenue growth rate of 62%. However, the company posted a net margin of -2.576% and a return on equity of -16.859%, indicating ongoing profitability challenges. The company is expected to release its next earnings report on August 4, 2026.

Analysts Set New Price Targets

On June 11, 2026, UBS maintained its hold rating on Clover Health with a price target of $4.75. Earlier, on June 4, Canaccord Genuity reiterated its buy rating with a target price of $4.2. The overall analyst consensus remains a buy, with an average target price of $4.15 based on three analyst opinions.

About Clover Health Investments, Corp.

Clover Health Investments, Corp. is a healthcare company based in Wilmington, Delaware. Founded in 2014, it provides Medicare Advantage plans, including preferred provider and health maintenance organization plans, to individuals eligible for Medicare. The company also operates Clover Assistant, a software platform designed to help physicians manage chronic diseases. With Andrew Toy at the helm as CEO, Clover Health employs 724 people.

Bottom Line

Karen Soares' sale of Clover Health shares is part of a planned transaction, reflecting routine insider activity. Clover Health's stock remains volatile, with a high beta and a forward P/E ratio suggesting future growth potential. Investors continue to watch institutional moves and analyst ratings closely, as these can signal broader market sentiment towards the company. As always, it's important to remember that insider transactions and analyst ratings provide insights into company dynamics but are not direct investment advice.